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The cerebrospinal fluid biomarker profile 
in an HIV-infected subject with Alzheimer’s 
disease
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Abstract 
It is a challenge to differentiate between HIV-associated neurocognitive disorders (HAND) and other types of neuro-
cognitive disease in the ageing HIV-infected population. Here we describe a 63 year old HIV-infected woman who 
had a history, neuropsychological test result, and PET examination consistent with characteristic Alzheimer’s disease 
(AD). The cerebrospinal fluid (CSF) biomarker profile was analogous to the profile typically found in AD in HIV-negative 
patients with increased t-tau and p-tau, a decreased level of Aβ42 and normal levels of CSF neurofilament light 
protein and sAPPα and sAPPβ, distinctly different from findings in HIV-associated dementia (HAD). Assessment of CSF 
biomarkers may be a valuable tool for clinicians to distinguish between HAD and AD.
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Background
Neurological complications were common features of 
HIV-infection before the era of effective antiretroviral 
treatment (ART) and more than 20% of HIV-infected 
patients without treatment developed HIV-associated 
dementia (HAD) in late disease [1]. Severe neurological 
complications are today rare in patients on suppressive 
ART [2] while milder forms of cognitive impairment are 
more frequently reported [3, 4]. Neurological complica-
tions have also been described in patients on ART with 
suppressed viral replication in plasma but detectable viral 
load in the CSF, so called symptomatic CSF escape [5, 6].
In HIV, a continuous immune activation of the cen-
tral nervous system (CNS) is still present despite sev-
eral years of otherwise effective ART [7, 8]. This chronic 
inflammation, together with a long lifespan of patients 
on ART, has raised concerns of whether HIV infection 
might interact with, or even potentiate, the development 
of other neurocognitive diseases such as AD. Older HIV-
infected persons may also be more at risk of developing 
HAND than younger individuals [9]. In any event, age-
related morbidity will be an increasing challenge in the 
aging HIV-infected population. The number of HIV-
infected patients, who develops neurocognitive diseases, 
including AD, will increase with time and it will become 
a challenge in those cases to differentiate between AD 
and different forms of HAND.
The CSF biomarker profile has been extensively stud-
ied in AD and a typical pattern is increased CSF levels 
of total (t-tau) and hyperphosphorylated protein tau 
(p-tau), indicating cortical neurodegeneration and tangle 
pathology, and decreased levels of amyloid-β1–42 (Aβ42), 
as a sign of senile plaque pathology [10]. In HAD, a slight 
different pattern could be found with normal p-tau, nor-
mal or increased t-tau, and normal or decreased Aβ42 
[11–16]. Other CSF markers, such as soluble amyloid 
precursor proteins (sAPPs) and neurofilament light pro-
tein (NFL) also have a different pattern in AD as com-
pared to HAD, with reduced sAPP levels and increased 
NFL levels in HAD (these levels are typically normal in 
AD) [11].
The CSF biomarker profile in patients with concomi-
tant disease has not yet been defined. Here we report 
CSF biomarkers in an HIV-infected patient with AD.
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Case presentation
The patient is a woman born in 1942 who was diagnosed 
with HIV 1998. She was infected sometimes between 
1994 and 1996. ART was initiated 1998 when her CD4-
cell count was 200 cells/μL. Plasma HIV RNA has been 
suppressed below 50 copies/μL since 2000, with only 
a few minor blips. CD4+ T cell count has remained 
between 800 and 1000 cells/μL for the last 8 years. The 
patient has a strong heredity of AD where her mother, 
two aunts on her mother’s side and her grandmother had 
AD with an onset between 70 and 80 years of age.
The patient’s cognitive impairment started in 2005 at 
the age of 63 years and since 2006 she has been an outpa-
tient at the Memory Clinic of Uppsala University Hospi-
tal. In 2006, minimal mental state examination (MMSE) 
showed 29 points out of 30, and in where she failed to 
perform the simple figure copying. A CT scan of the 
brain in 2006 showed no signs of abnormality. A more 
extensive neuropsychological examination was done in 
2007 and it showed predominantly normal results except 
for a very low performance in spatial short time mem-
ory and spatial episodic memory corresponding to right 
side posterior cortical functions. The conclusion was an 
overall good cognitive ability but with a selected cog-
nitive impairment in spatial abilities corresponding to 
the patient’s own experiences. Repeated MMSE evalua-
tion were initially stable, but a substantial performance 
decrease was revealed after 2011 (October 2006: 29, 
April 2009: 29, October 2009: 28, November 2010: 26, 
November 2011: 28, December 2012: 21, and October 
2014: 18). In October 2009 a PET-FDG examination was 
done that showed decreased glucose uptake bilaterally in 
the apical parts of the parietal lobes, decreased uptake 
in the left anterior singulum and in the basal parts of 
the parietal lobes and the right posterior thalamus, all 
findings conclusive with neurodegeneration typical for 
AD with a frontal involvement. ApoE testing was not 
accomplished.
In November 2009, the patient described her problems 
as a change in temper, being nearer to tears, having less 
tolerance for stress, problems finding her way around and 
problems finding words. She started medication for AD 
with colinesterasinhibitor donepezil 5 mg qd in addition 
to her other prescribed medications: venlafaxine, rosu-
vastatin, cetirizin and ART (lamivudine, abacavir, lopi-
navir and ritonavir). In 2010, donepezil was changed to 
galantamine 8 mg qd due to side effects. After 2011, the 
patient had increased memory difficulties and decreased 
stress tolerance. She had difficulties to cook and was 
unable to bake. Her problems with orientation increased 
even at home. Her husband described her short-term 
memory as substantially decreased and he had to remind 
her of her medication. In 2012 the AD treatment with 
galantamine was increased to 24 mg qd. Raltegravir was 
temporarily added to her ART in October 2010 for a few 
months but was halted when CSF HIV RNA remained 
suppressed.
CSF analyses
Lumbar punctures (LP:s) were performed on five occa-
sions between January 2010 and May 2011, both for dif-
ferential diagnostic purposes and to assess the potential 
impact by HIV on the cognitive impairment. CSF NFL, 
t-tau, p-tau, Aβ42, sAPPα and sAPPβ were analyzed 
with methods described elsewhere [11, 17, 18] or by the 
manufacturer (NF-light ELISA kit; Uman Diagnostics 
AB, Umeå, Sweden) and results are presented in Fig-
ure 1. The CSF biomarker profile showed a pattern with 
high t-tau with a mean value of 1,200 ng/L (range 1,080–
1,350  ng/L) (ref <400  ng/L), high p-tau with a mean of 
169  ng/L (range 153–182  ng/L) (ref <80  ng/L) and a 
marked decreased mean level, 212 ng/L, of Aβ42 (range 
130–280 ng/L) (ref >450 ng/L). The NFL measurements 
were slightly higher than in HIV-negative subjects with 
AD, but significantly lower than in patients with HAD. 
The NFL values were all close to the upper normal ref-
erence level (<1,850 ng/L above 59 years), and above the 
age-dependent cut-off level in one of the five samples 
(1,890 ng/L). sAPPα and sAPPβ were, in accordance with 
AD, not decreased, with mean values of 970 ng/L (range 
826–1,117  ng/L) and 377  ng/L (range 305–423  ng/L) 
respectively.
In addition, CSF was analyzed for HIV RNA, white 
blood cell (WBC) count, β2-microglobulin, neopterin, 
IgG and albumin. Serum and plasma was sampled for 
HIV RNA, CD4 cell count, albumin, IgG, neopterin and 
β2-microglobulin. At the first sampling CSF HIV RNA 
was elevated with 221 copies/mL, with a correspond-
ing plasma HIV RNA level of 46 copies/mL. On the fol-
lowing CSF exams, CSF HIV RNA was suppressed (<50 
copies/mL). Plasma HIV viral load was below 50 copies/
mL on all five occasions. The immunological analyses 
showed a continuously intact blood–brain-barrier with 
a normal albumin ratio and CSF WBC count was nor-
mal (0–3  cells/uL). CSF neopterin was elevated with a 
mean value of 6.6 and demonstrated an increased from 
4.7 to 8.4 during the time period (ref <5.8 nmol/L). CSF 
β2-microglobulin was slightly elevated, mean 2 (range 
1–2.5 mg/L) (ref <1.8 mg/L).
Discussion
Due to the effectiveness of ART and increased access to 
treatment, the HIV cohort is ageing and life-expectancy 
is increasing [20–22]. The prevalence of age-related co-
morbidities is increasing in the HIV-infected population 
[23].
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In this report, we present the biomarker profile in a 
patient with treated HIV-infection who developed cogni-
tive decline at the age of 63 years. Her history and clini-
cal presentation was consistent with AD, but HIV-related 
neurodegenerative disorders and symptomatic CSF 
escape [5, 6] had to be considered. Repeated LPs was per-
formed and the biomarker profile showed an AD-pattern 
with markedly lowered CSF Aβ42 and elevations of t-tau 
and p-tau.
In AD, the characteristic histopathological findings are 
extracellular accumulations of amyloid β in senile plaques 
and intracellular neurofibrillary tangles of hyperphospho-
rylated tau [24–26]. The biomarker profile in CSF reflects 
the changed protein metabolism in AD. The decreased 
level of Aβ42 is believed to be a result of the aggrega-
tion into plaques, and an elevated level of CSF t-tau and 
p-tau caused by neuronal damage and the formation of 
neurofibrillary tangles of hyperphosporylated tau protein 
[10]. Proteolytic processing of the amyloid precursor pro-
tein (APP) by either α- or β-secretase results in the two 
soluble forms sAPP-α and sAPP-β which remain unal-
tered or mildly elevated in AD [10]. sAPP-α and sAPP-β 
decrease, often prominently, in HAD [11, 13]. The mech-
anism behind this is not known, but interestingly, sAPPs 
and also Aβ42 decrease significantly also in HIV-infected 
patients with opportunistic infections [11] and in HIV-
negative subjects with other CNS infections [27, 28]. The 
patient in this report had normal levels of sAPPs.
NFL is the main component of large myelinated axons 
and a CSF biomarker of subcortical neuronal damage. As 
a marker of white matter disease, levels are elevated in 
other conditions such as vascular dementia [29], fronto-
temporal dementia [30] and MS [30, 31]. In AD, NFL 
may be moderately elevated [29, 32], particularly in older 
patients where a mixed pathology of other diseases, such 
as vascular dementia, may be present [19] and patients 
with late onset AD who may demonstrate white matter 
pathology on radiological investigation [33]. Very high 
levels of NFL are normally found in patients with HAD 
[34, 35]. Our patient had only slightly increased CSF 
NFL, much lower than patients with HAD.
Neuroinflammation, demonstrated by elevations of 
immunological markers in CSF such as WBC, neopterin, 
β2 microglobulin, MCP-1, IL-10 and TNF α, among oth-
ers, is well established as a consequence of CNS HIV 
infection. Inflammation may also persist in patients on 
stable ART despite viral suppression in CSF [8, 36]. Neu-
roinflammation also occurs in AD, however studies have 
mostly investigated markers of glial activation and results 



















































































































































































































































Figure 1 The concentrations of the CSF biomarkers analyzed in the reported case (AD HIV-pos) as compared to HIV-negative controls, neu-
roasymptomatic untreated HIV-infected (NA), HIV-associated dementia (HAD), and HIV-negative Alzheimer’s disease (AD) obtained from previous 
studies: a–e [11]; AD in f [19], other groups [11]. Boxes encompass interquartile ranges (IQR) with median (line) and mean (“ + ”), while whiskers 
designate 10th–90th percentiles.
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marker is proposed in the criteria for AD [37]. This 
patient showed a mild elevation in both neopterin and 
β2-microglobulin, which is a normal finding in patients 
with HIV-infection.
AD developed at an earlier age in this patient as com-
pared to other family members and it cannot be excluded 
that her HIV infection, and a possible HIV CSF escape, 
contributed to an accelerated progression of the AD-
process and neurocognitive decline. Interestingly, the 
levels of AD-related biomarkers in our case where at it´s 
extremes of the distribution for HIV-negative patients 
with AD. However, it is not possible to draw any gen-
eral conclusions from a single case and more studies are 
needed to define the detailed CSF biomarker profile in 
HIV-infected patients with AD.
Conclusion
It is of great importance to define differential diagnostic 
tools for HIV-infected patients developing non-HIV-
related neurocognitive disorders such as AD. There have 
been no studies of the CSF profile in patients with both 
HIV and AD presented in the literature so far and this is, 
to our knowledge, the first case presented. This patient 
had a clinical symptomatology and PET-scan result con-
sistent with AD, and the CSF analyses corresponded with 
the diagnosis and were distinctive from those found in 
HAD. The biomarker profile was not overtly affected by 
the HIV infection, and this case report suggest that the 
CSF biomarker profile can be used to differentiate AD 
from HIV-associated cognitive disorder in patients with 
well treated HIV-infection.
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